Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

Alnylam Pharmaceuticals Inc. won expanded approval for a heart drug that could be the biggest boon yet for the 23-year-old ...

(Reuters) -Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional ...

Pfizer will sell its remaining stake in British consumer healthcare group Haleon , the companies said on Tuesday.

The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA ...

Pfizer (NYSE:PFE – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a research ...

Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's ...

With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. | After charting similar moves ...

Pfizer (PFE) closed the most recent trading day at $26.21, moving -0.38% from the previous trading session. This move lagged the S&P 500's daily gain of 1.08%. Meanwhile, the Dow gained 0.92%, and the ...

Pfizer has raised £2.5 billion by offloading its remaining 7.3% stake in Haleon, the Panadol and Sensodyne business it used ...

Pfizer sold its entire 7.3% shareholding in London-listed consumer-health company Haleon for a net sum of 2.5 billion pounds ($3.25 billion). Pfizer sold 618 million shares for 385 pence each. The ...